<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">OJIM</journal-id><journal-title-group><journal-title>Open Journal of Internal Medicine</journal-title></journal-title-group><issn pub-type="epub">2162-5972</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ojim.2021.113011</article-id><article-id pub-id-type="publisher-id">OJIM-111758</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Chronic Nephropathies in the Internal Medicine Department of the Sylvanus Olympio University Hospital
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Agbeko</surname><given-names>Kodjo Djagadou</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Toyi</surname><given-names>Tchamdja</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Abdou-Bakari</surname><given-names>Tchala</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Yawovi</surname><given-names>Mawufemo Tsevi</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Abago</surname><given-names>Balaka</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Awalou</surname><given-names>Mohaman Djibril</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>Department of Internal Medicine, Sylvanus Olympio University Hospital, University of Lomé, Lomé, Togo</addr-line></aff><aff id="aff3"><addr-line>Department of Nephrology and Hemodialysis, Sylvanus Olympio University Hospital, University of Lomé, Lomé, Togo</addr-line></aff><aff id="aff2"><addr-line>Department of Internal Medicine, Kara University Hospital, University of Kara, Kara, Togo</addr-line></aff><pub-date pub-type="epub"><day>16</day><month>08</month><year>2021</year></pub-date><volume>11</volume><issue>03</issue><fpage>140</fpage><lpage>150</lpage><history><date date-type="received"><day>2,</day>	<month>July</month>	<year>2021</year></date><date date-type="rev-recd"><day>4,</day>	<month>September</month>	<year>2021</year>	</date><date date-type="accepted"><day>7,</day>	<month>September</month>	<year>2021</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Introduction: The chronic nephropathies constitute a real global public health concern due to the constant increase in the prevalence estimated between 10% and 15%. In Sub-Saharan Africa, this prevalence has been estimated at 13.9%. This study will allow knowing the epidemiological, clinical, paraclinical and etiological aspects of chronic kidney disease in the internal medicine department of CHU-SO Lom&#233;. 
  Method: This was a cross-sectional, retrospective and descriptive study. It concerned all the patients suffering from a chronic kidney disease, hospitalized between the 1st of January 2014 and the 31st of December 2018, for a duration of 5 years. 
  Results: During our study, 330 cases of chronic nephropathy were identified. The prevalence of chronic kidney disease was 8.3% of admissions. The mean age of the patients was 46.3 years with extremes of 19 and 86 years and a sex ratio of 1.32. A low socio-economic level of patients was observed in 63.9% with an urban origin in 69.7%. The main risk factors for renal impairment were hypertension (55.2%), diabetes mellitus (29.1%), obesity (20.6%), use of nephrotoxic products (19.4%), HIV infection (17%) and smoking (16.1%). The causes were dominated by nephroangiosclerosis (33.3%), followed by diabetic nephropathy (25.5%) and HIV-associated nephropathy (17%). Chronic renal failure was present in 95.8% of cases and was end stage in 69.7% of cases. Anemia was the main complication during the evolution of chronic kidney disease (98.2%). Mortality was 57.3% during hospitalization. 
  Conclusion: Chronic kidney disease is a fairly common reason for hospitalization in the internal medicine department. Emphasis should therefore be placed on preventive measures for hypertension, diabetes and HIV.
 
</p></abstract><kwd-group><kwd>Chronic Kidney Disease</kwd><kwd> Profile</kwd><kwd> CHU</kwd><kwd> Lom&#233; (Togo)</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Chronic nephropathies (CNP) are defined by the presence of markers of renal damage (structural or functional) and/or a decrease in estimated glomerular filtration rate (eGFR) &lt; 60 ml/min/1.73m<sup>2</sup> [<xref ref-type="bibr" rid="scirp.111758-ref1">1</xref>] for more than three months. They constitute a real global public health concern due to the constant increase in the prevalence estimated between 10% and 15% [<xref ref-type="bibr" rid="scirp.111758-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.111758-ref3">3</xref>]. In Sub-Saharan Africa, this prevalence has been estimated at 13.9% [<xref ref-type="bibr" rid="scirp.111758-ref4">4</xref>]. Projections for 2030 predict that more than 70% of the world’s population with end-stage renal disease (ESRD) will end up in developing countries, including most of the countries of Sub-Saharan Africa [<xref ref-type="bibr" rid="scirp.111758-ref4">4</xref>]. The cost of medical care for patients with CNP is very high according to the International Society of Nephrology (ISN) [<xref ref-type="bibr" rid="scirp.111758-ref5">5</xref>]. In Togo, the average global cost of care for a non-dialyzed CKD patient, hospitalized at the Sylvanus Olympio University Hospital (CHU-SO) in Lom&#233; amounted to 199.289.4 FCFA i.e. 5.7 times the Guaranteed Minimum Interprofessional Wage (SMIG) [<xref ref-type="bibr" rid="scirp.111758-ref6">6</xref>]. When the patient is on dialysis, the average annual cost including hemodialysis and medical expenses was 11,422,490.7 FCFA [<xref ref-type="bibr" rid="scirp.111758-ref7">7</xref>] and could be higher in private clinics.</p><p>Faced with this important medico-economic issue, the prevention of CNP becomes a necessity and implies a better knowledge of the profile of patients suffering from CNP. This work was carried out to describe the global profile of chronic nephropathies. The specific objectives were to:</p><p>- Describe the epidemiological aspects of chronic nephropathies.</p><p>- Describe the clinical and paraclinical aspects of chronic nephropathies.</p><p>- Describe the pathologies associated with chronic nephropathies.</p></sec><sec id="s2"><title>2. Framework and Method</title><p>The internal medicine department of the Sylvanus Olympio University Hospital (CHU-SO) served as the study setting. This was a descriptive and cross-sectional study with retrospective data collection. It focused on the records of patients suffering from chronic nephropathy, hospitalized in the internal medicine department of the CHU-SO from January 1, 2016 to December 31, 2021, i.e. a period of 5 years. We extracted deidentified data from the unit registry.</p><p>Were included in this study, all patients aged 16 years and over, hospitalized during the study period in the internal medicine department, having presented a chronic nephropathy defined by the presence for more than 3 months, of markers of renal damage that were:</p><p>- morphological abnormalities of the renal parenchyma on ultrasound (small kidney &lt; 10 cm, large kidney &gt; 120 cm, loss of differentiation) and/or</p><p>- biological abnormalities (proteinuria, albuminuria, hematuria, leukocyturia, and/or decrease in glomerular filtration rate (GFR) below 60 mL/min/1.73m<sup>2</sup>)</p><p>Glomerular filtration rate is estimated by calculating serum creatinine clearance according to the simplified MDRD (Modified Diet in Renal Diseases) [<xref ref-type="bibr" rid="scirp.111758-ref1">1</xref>].</p><p>All patients with chronic nephropathy receiving hemodialysis or having already undergone transplantation before admission to the department were excluded.</p><p>In the absence of a renal puncture biopsy, the following semiological classification was adopted to identify the type of initial nephropathy:</p><p>&#183; Chronic glomerular nephropathies (CGN): they were defined by proteinuria &gt; 1 g/24 hours, microscopic or macroscopic hematuria, more or less important hydrosodic retention (edemas) preceding arterial hypertension (HTA) and small regular symmetrical kidneys.</p><p>&#183; Chronic tubulointerstitial nephropathies (CTIN): they were defined by proteinuria &lt; 1 g/24h, non-glomerular type, leukocyturia, tubular abnormalities (hyperchloremic acidosis, sodium loss), often absent hypertension and small, irregular, bumpy, sometimes asymmetrical kidneys with calicar abnormalities in case of chronic pyelonephritis</p><p>&#183; HIV-associated nephropathy or HIVAN: the clinical picture usually occurs in a context of severe HIV-related immunosuppression (CD4 &lt; 200/mm<sup>3</sup>, and/or high viral load). It combines glomerular-type proteinuria with rapidly progressing renal failure, but with little or no edema. The kidneys are hyperechoic and increased in size on ultrasound.</p><p>&#183; Diabetic nephropathy (DN): it is defined by the presence in a long-term diabetic of microalbuminuria between 150 and 300 mg/24h associated with an inactive urinary sediment and diabetic retinopathy.</p><p>&#183; Chronic vascular nephropathies (CVN): defined by proteinuria &lt; 1 g/24h, hematuria most often irregular, constant hypertension often old and main symptom and small kidneys often irregular. Atherosclerotic disease or stenosis of the renal arteries may be associated with it on echodoppler.</p><p>&#183; Nephro-angiosclerosis (NAS) is defined by the presence of CKD in a long-term hypertensive patient, associated with albuminuria &lt; 500 mg/24h, inactive urinary sediment, hypertensive retinopathy and left ventricular hypertrophy.</p><p>&#183; Hereditary nephropathies (NH): these essentially group together autosomal dominant polycystic kidney disease.</p><p>&#183; Unclassifiable chronic nephropathies (UCN) are those whose semiology does not allow them to be classified in one of the groups.</p><p>- Chronic kidney disease (CKD) defined by: Renal history: old creatinemia &gt; 3 months and high, Biological arguments (anemia, hypocalcemia, hyperphosphatemia), radiological arguments (kidney size &lt; 100 mm), and/or a GFR &lt; 60 mL/min/1.73m<sup>2</sup> (according to MDRD)</p>Study Techniques<p>The medical records carried out by the doctors were used to collect the data collected on a survey form.</p><p>&#183; Sociodemographic characteristics: age, gender, profession, place of origin, socioeconomic group.</p><p>&#183; Associated factors: current or past smoking or alcohol use; lack of physical activity; family history of diabetes mellitus, hypertension and kidney disease; personal history of hypertension, diabetes mellitus, heart disease, dyslipidemia, kidney disease, gout, sickle cell disease, HIV infection, systemic disease; notion of taking non-steroidal anti-inflammatory drugs (NSAIDs) or other nephrotoxic products, traditional products; notion of repeated urinary tract infection.</p><p>&#183; Socioeconomic level (SEL) was subdivided into three groups according to the patients’ supposed income: high SEL when the income is estimated above 150,000 FCFA per month, average SEL when the income is between 35,000 and 150,000 FCFA per month, low SEL when the income is less than or equal to 35,000 FCFA per month i.e. the minimum wage.</p><p>&#183; Social coverage through either private or public health insurance (National Institute of Health Insurance)</p><p>&#183; Clinical parameters: Hypertension (HTA) defined by an SBP ≥ 140 mm Hg and/or a DBP ≥ 90 mmHg; diabetes mellitus defined by fasting glycemia ≥ 126 mg/dl; body mass index (BMI) defined by weight/height squared (kg/m<sup>2</sup>): BMI ≥ 30 (obesity); BMI between 25 - 29.9 (overweight); BMI between 18.5 - 24.9 (normal); BMI &lt; 18.5 (thinness); Chronic kidney disease was classified according to KDIGO 2012 (<xref ref-type="table" rid="table1">Table 1</xref>) [<xref ref-type="bibr" rid="scirp.111758-ref1">1</xref>].</p><p>&#183; Data and Statistical analysis</p><p>All data were entered into a data entry mask developed in Epi data version 3.1 software and then analyzed using IBM SPSS Statistics 20 statistical software.</p><p>Categorical data were expressed as percentages. The chi-square test was used to compare proportions. A p-value &lt; 5% was considered statistically significant.</p><p>&#183; Creatinine was measured using the Jaff&#233; colorimetric method.</p><p>&#183; Urinary sediment is sought in fresh morning urine and proteinuria by collecting 24-hour urine.</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Classification of chronic kidney disease according to KDIGO 2012</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Stage</th><th align="center" valign="middle" >Description</th><th align="center" valign="middle" >GFR (ml/min/1.73m&#178;)</th></tr></thead><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" >Renal impairment with normal or increased GFR</td><td align="center" valign="middle" >&gt;90</td></tr><tr><td align="center" valign="middle" >2</td><td align="center" valign="middle" >Renal impairment with slightly reduced GFR</td><td align="center" valign="middle" >60 - 90</td></tr><tr><td align="center" valign="middle" >3</td><td align="center" valign="middle" >Moderate kidney disease</td><td align="center" valign="middle" >30 - 60</td></tr><tr><td align="center" valign="middle" >4</td><td align="center" valign="middle" >Severe kidney disease</td><td align="center" valign="middle" >15 - 30</td></tr><tr><td align="center" valign="middle" >5</td><td align="center" valign="middle" >End-stage kidney disease</td><td align="center" valign="middle" >&lt;15</td></tr></tbody></table></table-wrap><p>&#183; The following ultrasound classification has been adopted for the renal echostructure: stage 0 or normal kidney for a hypoechoic renal cortex relative to that of the liver; stage I for an isoechoic renal cortex relative to the liver; stage II for a renal cortex that is hyperechoic relative to the liver but hypoechoic relative to the renal sinus with preservation of cortico-medullary differentiation; and stage III for a hyperechoic renal cortex relative to the liver and isoechoic relative to the renal sinus with disappearance of cortico-medullary differentiation.</p></sec><sec id="s3"><title>3. Results</title><sec id="s3_1"><title>3.1. Socio-Demographic Data</title><p>During our study, 3988 patients were hospitalized in the internal medicine department among whom we identified 330 cases of chronic nephropathy according to the predefined criteria. The prevalence of CNP in the department was 8.3% of admissions. There were 188 men i.e. 57% and 142 women i.e. 43% with a sex ratio (M/F) of 1.32. The mean age was 46.3 &#177; 14.4 years with extremes of 19 and 86 years. The 35 - 44 age group was the most affected.</p><p>The socio-economic level (SEL) in 63.9% of cases is low with a precarious financial situation.</p><p>Only 8% of the patients are senior executives. The majority of patients, i.e. 81%, did not have health insurance coverage. Among the patients who had health insurance, 13% were insured with INAM, the public insurance company. The majority of our patients, i.e. 69.7%, lived in urban areas.</p></sec><sec id="s3_2"><title>3.2. Clinical Data</title>Associated Clinical Etiological Factors<p>Known hypertension in 55.2% of patients was the main risk factor, followed for diabetes in 29.1% of cases. The distribution of patients according to the associated factors is shown in <xref ref-type="table" rid="table2">Table 2</xref>.</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Distribution of patients according to associated factors</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >Male</th><th align="center" valign="middle" >Female</th><th align="center" valign="middle" >Total</th><th align="center" valign="middle" >%</th></tr></thead><tr><td align="center" valign="middle" >HTA</td><td align="center" valign="middle" >110</td><td align="center" valign="middle" >72</td><td align="center" valign="middle" >182</td><td align="center" valign="middle" >55.2</td></tr><tr><td align="center" valign="middle" >Alcohol intake</td><td align="center" valign="middle" >96</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >110</td><td align="center" valign="middle" >33.3</td></tr><tr><td align="center" valign="middle" >Diabetes mellitus</td><td align="center" valign="middle" >65</td><td align="center" valign="middle" >31</td><td align="center" valign="middle" >96</td><td align="center" valign="middle" >29.1</td></tr><tr><td align="center" valign="middle" >Obesity</td><td align="center" valign="middle" >50</td><td align="center" valign="middle" >46</td><td align="center" valign="middle" >96</td><td align="center" valign="middle" >29.1</td></tr><tr><td align="center" valign="middle" >Use of medicinal plants</td><td align="center" valign="middle" >26</td><td align="center" valign="middle" >38</td><td align="center" valign="middle" >64</td><td align="center" valign="middle" >19.4</td></tr><tr><td align="center" valign="middle" >HIV</td><td align="center" valign="middle" >22</td><td align="center" valign="middle" >34</td><td align="center" valign="middle" >56</td><td align="center" valign="middle" >17</td></tr><tr><td align="center" valign="middle" >Tobacco exhibition</td><td align="center" valign="middle" >53</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >53</td><td align="center" valign="middle" >16.1</td></tr><tr><td align="center" valign="middle" >Use of Non-Steroidal Antti-inflammatory Drugs</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >5.2</td></tr><tr><td align="center" valign="middle" >Repeated urinary tract infections</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >5.5</td></tr><tr><td align="center" valign="middle" >Chronic viral hepatitis</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >3.6</td></tr></tbody></table></table-wrap><p>HTA = High Blood pressure, HIV = Human Immuno-depression Virus.</p></sec><sec id="s3_3"><title>3.3. Paraclinical Data</title><sec id="s3_3_1"><title>3.3.1. Renal Biological Data</title><p>The distribution of mean and extreme values of renal data can be found in <xref ref-type="table" rid="table3">Table 3</xref>.</p><p>Cytobacteriological urine test (CBEU) was performed in 110 patients. It revealed a urinary tract infection in 16.4% of cases (18/110 examinations) of which 6 cases were responsible for NICT. The germs found were: Klebsiella pneumoniae 8 cases (44.4%), Escherichia coli 2 cases (11.1%), Enterobacter aerogenes 2 cases (11.1%), Pseudomonas aeroginosa 2 cases (11.1%), Staphylococcus aureus 2 cases (11.1%).</p><p>The study of the different fractions had shown a predominance of: hypercholesterolemia &gt; 2 g/l in 36.8%, hypertriglyceridemia &gt; 1.50 g/l in 48.1%.</p></sec><sec id="s3_3_2"><title>3.3.2. Type of Chronic Nephropathies</title><p>We observed a predominance of glomerular nephropathies in 152 cases (46.1%), followed by chronic vascular nephropathies 110 cases (33.3%), diabetic nephropathies 36 cases (10.9%) and chronic tubulointerstitial nephropathies 32 cases (9.6%).</p></sec><sec id="s3_3_3"><title>3.3.3. Stages of Chronic Kidney Disease</title><p>The majority of patients had end-stage CKD, i.e. 69.7%. <xref ref-type="fig" rid="fig1">Figure 1</xref> shows the distribution of patients according to CKD stages</p></sec><sec id="s3_3_4"><title>3.3.4. Causal Pathologies of CNPs</title><p>Unbalanced hypertension (33.3%), unbalanced diabetes (25.5%) and HIV (17%) were the main probable causes of CNPs. The toxic origin was related to the use of medicinal plants and the other origins included 8 HBV and 4 HCV. The cases of obstructive uropathy were due to 6 prostate adenocarcinomas and 2 cervical neoplasia.</p></sec></sec><sec id="s3_4"><title>3.4. Evolving Data</title><sec id="s3_4_1"><title>3.4.1. Main Complications of CNP</title><p>Anemia is the main complication of CNP in 98.2%. <xref ref-type="table" rid="table4">Table 4</xref> shows the distribution of major complications of CNPs.</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Mean and extreme values of nitrogenous waste</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >Average</th><th align="center" valign="middle" >Standard deviation</th><th align="center" valign="middle" >Minimum</th><th align="center" valign="middle" >Maximum</th></tr></thead><tr><td align="center" valign="middle" >Uremia (g/l)</td><td align="center" valign="middle" >1.85</td><td align="center" valign="middle" >1.07</td><td align="center" valign="middle" >0.17</td><td align="center" valign="middle" >4.78</td></tr><tr><td align="center" valign="middle" >Creatinemia (mg/l)</td><td align="center" valign="middle" >130.33</td><td align="center" valign="middle" >104.30</td><td align="center" valign="middle" >12.0</td><td align="center" valign="middle" >510.0</td></tr><tr><td align="center" valign="middle" >Uricemia (mg/l)</td><td align="center" valign="middle" >97.21</td><td align="center" valign="middle" >32.73</td><td align="center" valign="middle" >15.0</td><td align="center" valign="middle" >176.0</td></tr><tr><td align="center" valign="middle" >24 h proteinuria (g)</td><td align="center" valign="middle" >1.7</td><td align="center" valign="middle" >1.6</td><td align="center" valign="middle" >0.4</td><td align="center" valign="middle" >7.9</td></tr></tbody></table></table-wrap><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Distribution of patients according to the main complications of CNP</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >Effective</th><th align="center" valign="middle" >%</th></tr></thead><tr><td align="center" valign="middle" >Anemia</td><td align="center" valign="middle" >324</td><td align="center" valign="middle" >98.2</td></tr><tr><td align="center" valign="middle" >HTA</td><td align="center" valign="middle" >220</td><td align="center" valign="middle" >82.4</td></tr><tr><td align="center" valign="middle" >APO*</td><td align="center" valign="middle" >116</td><td align="center" valign="middle" >35.2</td></tr><tr><td align="center" valign="middle" >Hematemesis</td><td align="center" valign="middle" >40</td><td align="center" valign="middle" >12.2</td></tr><tr><td align="center" valign="middle" >Coma</td><td align="center" valign="middle" >34</td><td align="center" valign="middle" >10.3</td></tr><tr><td align="center" valign="middle" >Phospho-calcium disorder</td><td align="center" valign="middle" >217</td><td align="center" valign="middle" >80.1</td></tr></tbody></table></table-wrap><p>*APO: Acute Pulmonary Oedema.</p></sec><sec id="s3_4_2"><title>3.4.2. Length of Hospitalization</title><p>The mean hospital stay was 15 &#177; 10.8 days, with extreme values of 2 and 67 days. This value of 67 days corresponds to the length of hospitalization of a patient with end-stage HIV-related CNP associated with nephrotic syndrome and a profound deterioration in general condition.</p></sec><sec id="s3_4_3"><title>3.4.3. Overall Mortality</title><p>Of the CNP patients with CKD requiring hemodialysis, only 56 (24.3%) had sufficient financial resources to access it.</p><p>One hundred and eighty-nine patients died during hospitalization, i.e. a mortality rate of 57.3%. The average age among the deceased was 46.8 &#177; 14.2 years. Anemia was the main cause of death in our series followed by APO 43 cases (22.7%) and severe sepsis 39 cases (20.6%).</p></sec></sec></sec><sec id="s4"><title>4. Discussion</title><sec id="s4_1"><title>4.1. Limitation of Study</title><p>This study suffered from the lack of renal biopsy which is important to improve the classification of the chronic nephropathies.</p></sec><sec id="s4_2"><title>4.2. Sociodemographic Aspect</title><p>The mean age was 46.3 &#177; 14.4 years with a peak in the age range 35 - 44 years i.e. 31.5%. This is similar to the results obtained in a meta-analysis published in The Lancet in 2014, where the most represented age range of patients from 13 sub-Saharan African countries, carriers of CNP, was 35 to 46 years [<xref ref-type="bibr" rid="scirp.111758-ref5">5</xref>]. This can be explained by the fact that this is the socially active population category that is easily exposed to certain environmental factors such as the use of alcohol, tobacco as well as medicinal plants that are sometimes nephrotoxic. Hypertension, one of the main causes of the disease, is also a factor affecting this category of the population due to social stress. This average age is lower than those obtained in developed countries where most patients are over 60 years old [<xref ref-type="bibr" rid="scirp.111758-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.111758-ref3">3</xref>]. This discrepancy between African and Western countries could be explained on the one hand by the young age of the African population and on the other hand by the greater accessibility to healthcare in industrialized countries and the aging of the Western population.</p></sec><sec id="s4_3"><title>4.3. Aspect of Associated Factors</title><p>The antecedents were dominated by hypertension (55.2%), alcoholism (33.3%), diabetes mellitus (29.1%), obesity (29.1%), use of medicinal plants (19.4%), HIV infection (17%) and smoking (16.1%). These antecedents are known to be important factors in the occurrence or worsening of CNP. Unbalanced hypertension and diabetes mellitus are one of the main causes of CKD in West Africa, ranging from 25% in Senegal to 29.8% in Nigeria, 48.7% where it is the cause of end–stage renal failure in 21% of patients [<xref ref-type="bibr" rid="scirp.111758-ref7">7</xref>]. Obesity has been identified as a risk factor for hypertension, diabetes and the occurrence of kidney disease [<xref ref-type="bibr" rid="scirp.111758-ref8">8</xref>]. Alcohol and tobacco consumption were significantly more common in men (p &lt; 0.001). A study conducted in patients with chronic nephropathy showed that GFR declined twice as fast in smokers as in non-smokers [<xref ref-type="bibr" rid="scirp.111758-ref9">9</xref>]. Another preventable risk factor for CNP is the use of herbal remedies, which was found in 19.4% of cases.</p><p>At this stage of observation, histopathological and toxicological studies are recommended to establish the causal relationship and the specific components of the incriminating products. HIV infection was reported in 17% in our study. As in a previous study, Sabi et al. [<xref ref-type="bibr" rid="scirp.111758-ref10">10</xref>] found a rate of 15.3% of patients infected with the HIV virus against a prevalence rate among the sexually active population (15 to 49 years) estimated at 3.2% in 2005 according to the United Nations Development Program (UNDP) in Togo. HIV is known to cause glomerular nephropathy, the typical HIVAN expression of which is histologically diagnosed [<xref ref-type="bibr" rid="scirp.111758-ref9">9</xref>]. Due to technical limitations, renal puncture biopsy was not performed. This remains a major challenge.</p></sec><sec id="s4_4"><title>4.4. Etiological Aspect of Chronic Nephropathies</title><p>The etiological research of CNP constitutes a difficult stage of the management in our regions, renal biopsy being rarely performed as well as immunological assessments. This difficulty could largely explain the non-negligible rate of undetermined causes of CNP reported in 10.9% in our study.</p><p>In our series, probable causes were dominated by nephro-angiosclerosis (33.3%), followed by diabetic nephropathy (25.5%) and HIV-associated nephropathy (17%). The same observation is made in most African studies where the known causes are by far dominated by nephro-angiosclerosis (NAS) with rates varying between 25% and 62.1% [<xref ref-type="bibr" rid="scirp.111758-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.111758-ref11">11</xref>] [<xref ref-type="bibr" rid="scirp.111758-ref12">12</xref>] [<xref ref-type="bibr" rid="scirp.111758-ref13">13</xref>].</p><p>On the contrary, Benja in Madagascar [<xref ref-type="bibr" rid="scirp.111758-ref14">14</xref>] and Bah in Guinea [<xref ref-type="bibr" rid="scirp.111758-ref15">15</xref>] had noted a predominance of chronic glomerulonephritis in 36.6% and 37.8% respectively, followed by NAS in 32.44% and 31.2% of cases. In developed countries, about 50% of severe kidney disease is the result of diabetes followed by hypertension [<xref ref-type="bibr" rid="scirp.111758-ref6">6</xref>].</p></sec><sec id="s4_5"><title>4.5. Stages of Chronic Nephropathy</title><p>The majority (69.7%) of our patients had chronic end stage nephropathy. Our result is similar to that of Benja [<xref ref-type="bibr" rid="scirp.111758-ref14">14</xref>] in Madagascar who found 75.31% of patients who were in the end-stage. The same observation was made by Naiker [<xref ref-type="bibr" rid="scirp.111758-ref7">7</xref>] who found more than 70% of end-stage CNP cases in most Sub-Saharan African countries. These data contrast with those of developed countries [<xref ref-type="bibr" rid="scirp.111758-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.111758-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.111758-ref16">16</xref>] where the majority of patients are seen before stage 3. This late presentation of CNP in our series would be due to the poor screening policy and insufficient education on CNP; all this based on the low socioeconomic level and the lack of universal health insurance. This results in an inadequacy of the therapeutic management. Indeed, due to lack of financial means, 75.7% of the patients could not benefit from a replacement therapy (hemodialysis or kidney transplant). The high hospital mortality during our study (57.3%) is therefore due to the absence of adequate treatment, as in C&#244;te d’Ivoire (54%) [<xref ref-type="bibr" rid="scirp.111758-ref17">17</xref>] and in Guinea Conakry 20.6% [<xref ref-type="bibr" rid="scirp.111758-ref15">15</xref>].</p></sec></sec><sec id="s5"><title>5. Conclusion</title><p>Chronic nephropathy is a real global public health concern, and its prevention requires a better knowledge of the profile of patients suffering from it. At the Sylvanus Olympio University Hospital, they represent 8.3% of admissions to the internal medicine department. They concerned young adults of low socioeconomic level seen in the majority of cases at the end stage of the disease requiring supplementary treatment. The main etiological factors are hypertension, diabetes mellitus and HIV. The high mortality was related to the lack of access to adequate care in the majority of cases. It is essential to focus on preventive measures, early detection and adequate treatment of risk factors for CNP.</p></sec><sec id="s6"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest regarding the publication of this paper.</p></sec><sec id="s7"><title>Cite this paper</title><p>Djagadou, A.K., Tchamdja, T., Tchala, A.-B., Tsevi, Y.M., Balaka, A. and Djibril, A.M. (2021) Chronic Nephropathies in the Internal Medicine De- partment of the Sylvanus Olympio University Hospital. Open Journal of Internal Me- dicine, 11, 140-150. https://doi.org/10.4236/ojim.2021.113011</p></sec></body><back><ref-list><title>References</title><ref id="scirp.111758-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Levey, A.S., de Jong, P.E., Coresh, J., Nahas, M.E.L., Astor, B.C., Matsushita, K., et al. (2011) The Definition, Classification, and Prognosis of Chronic Kidney Disease: A KDIGO Controversies Conference Report. Kidney International, 80, 17-28. https://doi.org/10.1038/ki.2010.483</mixed-citation></ref><ref id="scirp.111758-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Chadban, S.J., Briganti, E.M., Kerr, P.G., Dunstan, D.W., Welborn, T.A., Zimmet, P.Z., et al. (2003) Prevalence of Kidney Damage Australian Adults: The AusDiab Kidney Study. Journal of American Society of Nephrology, 14, S131-S138. https://doi.org/10.1097/01.ASN.0000070152.11927.4A</mixed-citation></ref><ref id="scirp.111758-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Stanifer, J.W., Jing, B., Tolan, S., Helmke, N., Mukerjee, R., Naicker, S., et al. (2014) The Epidemiology of Chronic Kidney Disease in Sub-Saharan Africa: A Systematic Review and Meta-Analysis. Lancet Global Health, 2, e174-e181. https://doi.org/10.1016/S2214-109X(14)70002-6</mixed-citation></ref><ref id="scirp.111758-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Sabi, K.A., Noto-Kadou-Kaza, B., et al. (2017) Co&amp;ucirec;t direct de la prise en charge de l’insuffisance rénale chronique non dialyse au Togo. Revue scientifique du Tchad, 1.</mixed-citation></ref><ref id="scirp.111758-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Djagadou, K.A., Tchamdja, T., Némi, K.D., Djalogue, L., Balaka, A. and Djibril, M.A. (2019) Co&amp;ucirec;t direct de la prise en charge des patients en insuffisance rénale chronique au centre hospitalier universitaire sylvanus olympio. Advance Research Journal of Multidisciplinary Discoveries, 33, 18-20.</mixed-citation></ref><ref id="scirp.111758-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Bah, A.O., et al. (2014) Morbidité et mortalité hospitalières dues à l’insuffisance rénale chronique dans un pays dont l’accès à la dialyse est limité. Néphrologie &amp; Thérapeutique, 10, 394.</mixed-citation></ref><ref id="scirp.111758-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Sabi, K.A., Gnionsahe, D.A. and Amedegnato, D. (2011) Chronic Kidney Failure in Togo: Clinical, Laboratory, and Etiological Aspects. Médecine Trop Rev Corps Santé Colon, 71, 74-76.</mixed-citation></ref><ref id="scirp.111758-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">National Kidney Foundation (2002) K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. American Journal of Kidney Diseases, 39, S1-266.</mixed-citation></ref><ref id="scirp.111758-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Couser, W.G., Remuzzi, G., Mendis, S. and Tonelli, M. (2011) The Contribution of Chronic Kidney Disease to the Global Burden of Major Noncommunicable Diseases. Kidney International, 80, 1258-1270. https://doi.org/10.1038/ki.2011.368</mixed-citation></ref><ref id="scirp.111758-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Naicker, S. (2013) End-Stage Renal Disease in Sub Saharan Africa. Kidney International Supplements, 3, 161-163. https://doi.org/10.1038/kisup.2013.4</mixed-citation></ref><ref id="scirp.111758-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Chinar, A. (2015) épidémiologie de l’insuffisance rénale chronique terminale à la da&amp;iuml;ra de Batna, Algérie. Néphrologie &amp; Thérapeutique, 11, 435. https://doi.org/10.1016/j.nephro.2015.07.212</mixed-citation></ref><ref id="scirp.111758-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Fouda, H., Nono, A., Kaze, F., Halle, M.-P., Mahamat, M. and Ashuntantang, G. (2017) épidémiologie de la Maladie Rénale Chronique à l’H&amp;ocirc;pital Général de Douala: étude Comparative entre Hommes et Femmes. Health Sciences and Disease, 18, 35-39.</mixed-citation></ref><ref id="scirp.111758-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Osafo, C., Mate-Kole, M., Affram, K. and Adu, D. (2011) Prevalence of Chronic Kidney Disease in Hypertensive Patients in Ghana. Renal Failure, 33, 388-392. https://doi.org/10.3109/0886022X.2011.565140</mixed-citation></ref><ref id="scirp.111758-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">OMS (2016) Profil sanitaire du Togo. https://www.who.int/countries/tgo/fr</mixed-citation></ref><ref id="scirp.111758-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Ramilitiana, B., Ranivoharisoa, E.M., Dodo, M., Razafimandimby, E. and Randriamarotia, W.F. (2016) A Retrospective Study on the Incidence of Chronic Renal Failure in the Department of Internal Medicine and Nephrology at University Hospital of Antananarivo. The Pan African Medical Journal, 23, Article No. 141.</mixed-citation></ref><ref id="scirp.111758-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Chen, W., Chen, W., Wang, H., Dong, X., Liu, Q., Mao, H., et al. (2009) Prevalence and Risk Factors Associated with Chronic Kidney Disease in an Adult Population from Southern China. Nephrology Dialysis Transplantation, 24, 1205-1212. https://doi.org/10.1093/ndt/gfn604</mixed-citation></ref><ref id="scirp.111758-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Ouattara, B., Kra, O., Yao, H. and Kadjo, K.N. (2011) Particularités de l’insuffisance rénale chronique chez des patients adultes noirs hospitalisés dans le service de médecine interne du CHU de Treichville. Néphrologie &amp; Thérapeutique, 7, 531-534. https://doi.org/10.1016/j.nephro.2011.03.009</mixed-citation></ref></ref-list></back></article>